Research programme: antiviral therapeutics - Seed Therapeutics
Latest Information Update: 05 Mar 2024
At a glance
- Originator Seed Therapeutics
- Class Antivirals
- Mechanism of Action Hepatitis B virus X protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Hepatitis B
Most Recent Events
- 11 Jan 2024 Early research in Hepatitis B in USA (unspecified route), prior to January 2024 (Seed Therapeutics pipeline, January 2024)